The spotlight has been on cannabis more and more these days, and this time, the light is a little more flattering. Last year, Congress passed the Farm Bill, legislation that legalized the cultivation of industrial hemp as long as it had less than 0.3% THC levels.
THC is the cannabinoid responsible for the high marijuana users experience, and it’s why cannabis is still illegal at the federal level. Industrial hemp, however, has negligible amounts of THC. It’s bred for cannabidiol (CBD) instead, one of the other main cannabinoids in the cannabis plant.
While it wouldn’t be factual to say CBD is responsible for the boom in demand for hemp, it accounts for a big portion of it. It is a potent and versatile medicine, said to be effective against a plethora of conditions ranging from anxiety and high blood pressure to chronic pain.
Although there’s little irrefutable research to back these claims up, there is plenty of anecdotal evidence painting CBD as a cure-all. The U.S. Food and Drug Administration has forbidden sellers from claiming their products have therapeutic benefits.
Even so, the industry is flush with thousands of CBD products ranging from tinctures, and topicals to CBD-infused beverages. More and more people are using CBD-infused products, with a large percentage doing it for pain relief.
However, what few realize is that cannabis is chock-full of cannabinoids, more than 120 actually, and we’ve only just scratched the surface. Beyond CBD and THC, there are dozens of other cannabinoids that could be beneficial, if not more.
One of them is cannabigerol or CBG. Usually appearing in low levels, less than 1%, it is considered a minor cannabinoid. The compound is a potent anti-inflammatory, and it’s shown great promise in clinical trials against cancer, inflammatory bowel disease, and glaucoma. It can clearly match up to the equally versatile CBD.
“CBG White,” a CBG-heavy strain by Florida-based company CultivAid, is one of the few CBG flowers being sold in Dallas. On its black and copper colored box, it says ‘CBG, often referred to as the mother cannabinoid, is a key wellness component of cannabis. CBG offers a plethora of benefits, exceeding expectations and shining through where other cannabinoids may have fallen short.’
Unlike THC-heavy strains which are illegal in Dallas, CBG-heavy cannabis strains are completely legal, and consumers will be happy to know that the purchase and use of such products will not attract any unwanted attention from law enforcement.
Industry watchers are of the view that the entire CBD industry, including entities like ChineseInvestors.com Inc. (OTCQB: CIIX) and IONIC Brands Corp. (CSE: IONC) (OTC: IONKF), welcome the addition of this newly commercialized cannabinoid since the more other cannabis compounds are exploited, the better for all sector players.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
